体外膜氧合期间补充抗凝血酶:一项先导性随机临床试验的研究方案
GATRA是一项前瞻性、随机、单盲、多中心、对照两臂先导试验,拟将接受静脉-静脉体外膜氧合(ECMO)的呼吸衰竭患者随机分为抗凝血酶(AT)补充组(维持功能性AT水平在80%至120%)与对照组,整个ECMO期间两组均按标准化方案使用普通肝素抗凝。主要终点为维持活化部分凝血活酶时间比值在1.5至2所需的肝素剂量,次要终点为抗凝充分性及出血和血栓并发症发生率。
要点
- 接受静脉-静脉ECMO的呼吸衰竭患者随机分为AT补充组与对照组,整个ECMO期间均按标准化方案使用普通肝素抗凝。
- AT补充组维持功能性AT水平在80%至120%,主要终点为维持活化部分凝血活酶时间比值在1.5至2所需的肝素剂量。
- 次要终点为抗凝充分性及出血和血栓并发症发生率。
核心结论
- GATRA是一项先导试验,将检验AT补充方案在减少肝素剂量和提高ECMO期间抗凝充分性方面的效果。
- 若结果阳性,可能为未来更大规模的试验提供基础,以验证AT补充对包括出血事件、输血需求和死亡率在内的复合终点的影响。
研究设计与样本
- GATRA是一项前瞻性、随机、单盲、多中心、对照两臂先导试验。
- 接受静脉-静脉ECMO的患者被随机分为AT补充组(维持功能性AT水平在80%至120%)或对照组(不补充AT),整个ECMO期间均按标准化方案使用普通肝素抗凝。
- 主要终点为维持活化部分凝血活酶时间比值在1.5至2所需的肝素剂量。
- 次要终点为抗凝充分性及出血和血栓并发症发生率。
- 试验注册于ClinicalTrials.gov,注册号NCT03208270,注册日期为2017年7月5日。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Normal levels of plasma antithrombin (AT) activity might decrease heparin requirements to achieve an adequate level of anticoagulation during treatment with extracorporeal membrane oxygenation (ECMO). Acquired AT deficiency during ECMO is common, but formal recommendations on target, timing, and rate of AT supplementation are lacking. Thus, we conceived a pilot trial to evaluate the feasibility and safety of prolonged AT supplementation in patients requiring veno-venous ECMO for respiratory failure. METHODS: Grifols Antithrombin Research Awards (GATRA) is a prospective, randomized, single blinded, multicenter, controlled two-arm trial. Patients undergoing veno-venous ECMO will be randomized to either receive AT supplementation to maintain a functional AT level between 80 and 120% (AT supplementation group) or not (control group) for the entire ECMO course. In both study groups, anticoagulation will be provided with unfractionated heparin following a standardized protocol. The primary endpoint will be the dose of heparin required to maintain the ratio of activated partial thromboplastin time between 1.5 and 2. Secondary endpoints will be the adequacy of anticoagulation and the incidence of hemorrhagic and thrombotic complications. DISCUSSION: GATRA is a pilot trial that will test the efficacy of a protocol of AT supplementation in decreasing the heparin dose and improving anticoagulation adequacy during ECMO. If positive, it might provide the basis for a future larger trial aimed at verifying the impact of AT supplementation on a composite outcome endpoint including hemorrhagic events, transfusion requirements, and mortality. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03208270 . Registered on 5 July 2017.
引用
- Panigada M, Spinelli E, Cucino A, et al. Antithrombin supplementation during extracorporeal membrane oxygenation: study protocol for a pilot randomized clinical trial. Trials. 2019. PMID: 31186035. doi:10.1186/s13063-019-3386-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。